Simpson Payton, Wallace Katie, Olney Katherine, Casaus Danielle, Burgess David S, Schadler Aric, Leonhard Abigail, VanHoose Jeremy
Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA.
Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington, KY, USA.
Antimicrob Steward Healthc Epidemiol. 2025 Aug 22;5(1):e191. doi: 10.1017/ash.2025.10101. eCollection 2025.
Currently, the Infectious Diseases Society of America (IDSA) Guidelines for Uncomplicated Urinary Tract Infections (UTIs) recommend a 3 to 7-day antibiotic course of oral beta-lactam agents when other recommended agents are not feasible. In recent years, studies have demonstrated efficacy in shorter courses of antimicrobial therapy for acute uncomplicated cystitis compared with longer courses, but there is limited data regarding intravenous beta-lactams for acute uncomplicated cystitis.
This single-center, retrospective, non-inferiority cohort study included adult patients admitted to University of Kentucky Albert B. Chandler Medical Center or Good Samaritan Hospital with acute uncomplicated cystitis. The primary outcome assessed was treatment failure, defined as the need for retreatment with additional antibiotic therapy within 30 days of antibiotic completion. Secondary outcomes include incidence of C. difficile infection within 30 days of antibiotic therapy, hospital readmission, and outpatient telephone encounters within 30 days of discharge. Patients were divided into the short course (those receiving three days or less of beta-lactam antibiotics and at least 1 day was IV) or the long course (those receiving four or more days of beta lactam antibiotics).
Overall, 52 patients met the criteria to be included in the final study, with 33 in the short course beta-lactam group and 19 in the long-course beta-lactam group. Failure rates between short and long course were 15.2% and 15.8% respectively (p=1.000). Ceftriaxone was the most commonly utilized antibiotic in both groups. The median total antibiotic duration between the long and short groups was 3 and 6 days respectively (p<0.001).
In hospitalized patients warranting initial IV therapy for acute uncomplicated cystitis, a 3-day total of beta-lactam therapy, with transition to oral, should be considered.
目前,美国感染病学会(IDSA)关于单纯性尿路感染(UTIs)的指南建议,当其他推荐药物不可行时,口服β-内酰胺类药物的抗生素疗程为3至7天。近年来,研究表明,与较长疗程相比,急性单纯性膀胱炎采用较短疗程的抗菌治疗具有疗效,但关于急性单纯性膀胱炎使用静脉注射β-内酰胺类药物的数据有限。
这项单中心、回顾性、非劣效性队列研究纳入了肯塔基大学阿尔伯特·B·钱德勒医学中心或撒玛利亚慈善医院收治的患有急性单纯性膀胱炎的成年患者。评估的主要结局是治疗失败,定义为在抗生素治疗结束后30天内需要额外的抗生素治疗进行再次治疗。次要结局包括抗生素治疗后30天内艰难梭菌感染的发生率、再次入院率以及出院后30天内的门诊电话随访情况。患者被分为短疗程组(接受β-内酰胺类抗生素治疗3天或更短时间且至少1天为静脉注射)或长疗程组(接受β-内酰胺类抗生素治疗4天或更长时间)。
总体而言,52例患者符合纳入最终研究的标准,其中短疗程β-内酰胺组33例,长疗程β-内酰胺组19例。短疗程组和长疗程组的失败率分别为15.2%和15.8%(p = 1.000)。头孢曲松是两组中最常用的抗生素。长疗程组和短疗程组的抗生素总疗程中位数分别为3天和6天(p<0.001)。
对于需要初始静脉治疗的急性单纯性膀胱炎住院患者,应考虑总共3天的β-内酰胺治疗,并过渡为口服治疗。